These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24999168)

  • 1. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
    Burgio SL; Conteduca V; Rudnas B; Carrozza F; Campadelli E; Bianchi E; Fabbri P; Montanari M; Carretta E; Menna C; De Giorgi U
    Clin Genitourin Cancer; 2015 Feb; 13(1):39-43. PubMed ID: 24999168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
    Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
    BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
    Conteduca V; Caffo O; Lolli C; Aieta M; Scarpi E; Bianchi E; Maines F; Schepisi G; Salvi S; Massari F; Carrozza F; Veccia A; Chiuri VE; Campadelli E; Facchini G; De Giorgi U
    Prostate; 2017 Jun; 77(9):1012-1019. PubMed ID: 28429372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
    Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
    Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
    Ueda Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Clin Genitourin Cancer; 2017 Apr; 15(2):320-325. PubMed ID: 27601278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
    Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
    J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
    Schiff JP; Cotogno P; Feibus A; Steinwald P; Ledet E; Lewis B; Sartor O
    BMC Cancer; 2019 May; 19(1):524. PubMed ID: 31151428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
    Fan L; Wang X; Chi C; Wang Y; Cai W; Shao X; Xu F; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Wang R; Zhou L; Dong B; Xue W
    Prostate; 2017 Sep; 77(12):1233-1241. PubMed ID: 28752926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
    BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
    Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J
    Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J; Yang Q; Chen XS; Tian J; Yao X
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
    Han KS; Hong SJ
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
    Sella A; Sternberg CN; Skoneczna I; Kovel S
    BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
    Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U
    Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.